SRRK Quote, Financials, Valuation and Earnings

Cytokinetics has a net margin of -- compared to Scholar Rock Holding's net margin of -34674.95%. Scholar Rock Holding's return on equity of -- beat Cytokinetics's return on equity of --.

Scholar Rock Holding has a consensus price target of $46.38, signalling upside risk potential of 4.31%. On the other hand Cytokinetics has an analysts' consensus of $81.71 which suggests that it could grow by 72.52%. Given that Cytokinetics has higher upside potential than Scholar Rock Holding, analysts believe Cytokinetics is more attractive than Scholar Rock Holding.

Scholar Rock Holding has a beta of 0.578, which suggesting that the stock is 42.249% less volatile than S&P 500. In comparison Cytokinetics has a beta of 0.796, suggesting its less volatile than the S&P 500 by 20.368%.

Scholar Rock Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Scholar Rock Holding pays -- of its earnings as a dividend. Cytokinetics pays out -- of its earnings as a dividend.

Scholar Rock Holding quarterly revenues are --, which are smaller than Cytokinetics quarterly revenues of $463K. Scholar Rock Holding's net income of -$64.5M is higher than Cytokinetics's net income of -$160.5M. Notably, Scholar Rock Holding's price-to-earnings ratio is -- while Cytokinetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scholar Rock Holding is 89.95x versus 1,574.06x for Cytokinetics. Usually stocks with elevated PS ratios are considered overvalued.

Ocugen has a net margin of -- compared to Scholar Rock Holding's net margin of -1141.73%. Scholar Rock Holding's return on equity of -- beat Ocugen's return on equity of -136.91%.

Scholar Rock Holding has a consensus price target of $46.38, signalling upside risk potential of 4.31%. On the other hand Ocugen has an analysts' consensus of -- which suggests that it could grow by 639.12%. Given that Ocugen has higher upside potential than Scholar Rock Holding, analysts believe Ocugen is more attractive than Scholar Rock Holding.

Scholar Rock Holding has a beta of 0.578, which suggesting that the stock is 42.249% less volatile than S&P 500. In comparison Ocugen has a beta of 3.823, suggesting its more volatile than the S&P 500 by 282.261%.

Scholar Rock Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Scholar Rock Holding pays -- of its earnings as a dividend. Ocugen pays out -- of its earnings as a dividend.

Scholar Rock Holding quarterly revenues are --, which are smaller than Ocugen quarterly revenues of $1.1M. Scholar Rock Holding's net income of -$64.5M is lower than Ocugen's net income of -$13M. Notably, Scholar Rock Holding's price-to-earnings ratio is -- while Ocugen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scholar Rock Holding is 89.95x versus 47.20x for Ocugen. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -- compared to Scholar Rock Holding's net margin of 36.03%. Scholar Rock Holding's return on equity of -- beat Regeneron Pharmaceuticals's return on equity of 17.19%.

Scholar Rock Holding has a consensus price target of $46.38, signalling upside risk potential of 4.31%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,053.08 which suggests that it could grow by 47.82%. Given that Regeneron Pharmaceuticals has higher upside potential than Scholar Rock Holding, analysts believe Regeneron Pharmaceuticals is more attractive than Scholar Rock Holding.

Scholar Rock Holding has a beta of 0.578, which suggesting that the stock is 42.249% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.084, suggesting its less volatile than the S&P 500 by 91.622%.

Scholar Rock Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Scholar Rock Holding pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Scholar Rock Holding quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. Scholar Rock Holding's net income of -$64.5M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, Scholar Rock Holding's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 17.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scholar Rock Holding is 89.95x versus 5.92x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Cassava Sciences has a net margin of -- compared to Scholar Rock Holding's net margin of --. Scholar Rock Holding's return on equity of -- beat Cassava Sciences's return on equity of --.

Scholar Rock Holding has a consensus price target of $46.38, signalling upside risk potential of 4.31%. On the other hand Cassava Sciences has an analysts' consensus of -- which suggests that it could grow by 4540%. Given that Cassava Sciences has higher upside potential than Scholar Rock Holding, analysts believe Cassava Sciences is more attractive than Scholar Rock Holding.

Scholar Rock Holding has a beta of 0.578, which suggesting that the stock is 42.249% less volatile than S&P 500. In comparison Cassava Sciences has a beta of -0.856, suggesting its less volatile than the S&P 500 by 185.551%.

Scholar Rock Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cassava Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Scholar Rock Holding pays -- of its earnings as a dividend. Cassava Sciences pays out -- of its earnings as a dividend.

Scholar Rock Holding quarterly revenues are --, which are smaller than Cassava Sciences quarterly revenues of --. Scholar Rock Holding's net income of -$64.5M is lower than Cassava Sciences's net income of -$27.9M. Notably, Scholar Rock Holding's price-to-earnings ratio is -- while Cassava Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scholar Rock Holding is 89.95x versus 2.74x for Cassava Sciences. Usually stocks with elevated PS ratios are considered overvalued.